Drug intelligence / Profile preview

Huizhisu (Huizhi Kangyuan)

Development stage
Unknown
Lead developer
Beijing Anding Hospital
Modality
Small Molecules
01

Overview

Huizhisu is a combination product primarily composed of phosphatidylserine (PS), docosahexaenoic acid (DHA), and taurine, which is investigated in China for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and cognitive enhancement. Phosphatidylserine is a critical phospholipid in neuronal membranes that supports membrane fluidity and serves as a cofactor for enzymes like protein kinase C. DHA is an omega-3 fatty acid essential for brain structure and function, while taurine acts as a neuromodulator and antioxidant. The combination is hypothesized to improve symptoms of ADHD by modulating neurotransmitter systems, including dopamine and acetylcholine, and enhancing neuronal signaling. Clinical trials, such as those conducted at Beijing Anding Hospital, have evaluated Huizhisu as a non-stimulant therapeutic option for children with ADHD.

Brand names
Huizhisu
Other names
慧智素Hui Zhi Su
02

Targets

Glycine receptorPKC (Protein kinase C family)

Beyond the preview

Go deeper on Huizhisu (Huizhi Kangyuan).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huizhisu (Huizhi Kangyuan).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call